Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|8|2|93-100

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.8, Iss.2, 2013-06, pp. : 93-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemotherapy in Elderly Patients with Advanced Lung Cancer Part II: Treatment of Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 27, Iss. 6, 2004-12 ,pp. : 583-588

Karger

Access to resources Recommend Favorite

Assessment of EGFR and KRAS mutation status from FNAs and core‐needle biopsies of non‐small cell lung cancer

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 4, 2015-04 ,pp. : 230-236

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeted therapy in lung cancer

By  

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. 3, 2015-04 ,pp. : 370-378

John Wiley & Sons Inc

Access to resources Recommend Favorite

A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non–small cell lung cancer (NSCLC)

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : 1321-1327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management

By  

Current Drug Safety, Vol. 11, Iss. 1, 2016-03 ,pp. : 62-68

Bentham Science Publishers

Access to resources Recommend Favorite